Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome

Adam Petrich, Brad Kahl, Howard Bailey, Kyungmann Kim, Nancy Turman, Mark Juckett

Research output: Contribution to journalArticlepeer-review

Abstract

We conducted a phase II trial of doxercalciferol, a vitamin D2 analogue, in 15 patients with MDS. Each received doxercalciferol 12.5μg orally daily for 12 weeks. Nine of 15 patients completed the prescribed course and of these, six had stable disease. No patient had a response (IWG criteria) and overall eight patients experienced progressive disease while on therapy. Two patients with chronic myelomonocytic leukemia (CMML) had a marked rise in monocytes on study. Overall the treatment was well tolerated. One patient was removed from study due to hypercalcemia. We conclude that short-term treatment with doxercalciferol has limited activity in patients with MDS.

Original languageEnglish (US)
Pages (from-to)57-61
Number of pages5
JournalLeukemia and Lymphoma
Volume49
Issue number1
DOIs
StatePublished - Jan 2008
Externally publishedYes

Keywords

  • Doxercalciferol
  • Myelodysplastic syndrome
  • Phase II study

Fingerprint

Dive into the research topics of 'Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome'. Together they form a unique fingerprint.

Cite this